EVOLUTION OF CYTOGENETIC PROFILES IN MULTIPLE MYELOMA: A RETROSPECTIVE ANALYSIS OF FISH CHANGES

EHA Library, Jorge Hurtado Martinez, 4161933

BIOLOGICAL FUNCTION AND PROGNOSTIC VALUE OF RAB26 IN PAN-CANCER: FOCUS ON ITS ROLE IN PREDICTING DISEASE PROGRESSION IN MULTIPLE MYELOMA

EHA Library, Bingjie Fan, 4161934

LINKING SURFACE PROTEIN EXPRESSION WITH CYTOGENETIC AND MOLECULAR GENETIC ALTERATIONS IN NEWLY DIAGNOSED MYELOMA PATIENTS

EHA Library, Veronika Ecker, 4161935

USE OF BIOSIMULATION TO PREDICT INDIVIDUAL PATIENT RESPONSE TO ANTI-CD38 THERAPY WHEN COMBINED WITH EITHER LENALIDOMIDE OR BORTEZOMIB IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, James Wingrove, 4161936

GENETIC POLYMORPHISM IN NRAS, KRAS, BRAF GENES IN MULTIPLE MYELOMA

EHA Library, Zhanna Kozich, 4161937

CYTOGENETIC RISK IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Tatiana Obukhova, 4161938

EARLY PHENOTYPIC T CELLS CHANGES PREDICT THE RESPONSE TO CD3XBCMA BISPECIFIC ANTIBODIES IN MULTIPLE MYELOMA

EHA Library, Yannick Simoni, 4161939

TRANSCRIPTOMIC ANALYSIS IDENTIFIES MOLECULAR DIFFERENCES BETWEEN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA THAT LEAD TO RESPONSE OR RESISTANCE TO INDUCTION THERAPY WITH PAD/VCD REGIMENS.

EHA Library, Anna Sergeeva, 4161940

THE MECHANISM OF STAT3 INHIBITORS INDUCING DNA DAMAGE IN MULTIPLE MYELOMA CELLS AND ENHANCING THE ANTI-TUMOR EFFECTS OF NK CELLS

EHA Library, Rong Fu, 4161941

IDENTIFICATION OF CERNA REGULATORY NETWORKS DRIVEN BY THE LNCRNA NEAT1 IN MULTIPLE MYELOMA

EHA Library, Domenica Ronchetti, 4161942

HAPLOTYPES IN THE IL-4 GENE IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Elena Kuzmich, 4161943

CAUSAL RELATIONSHIPS BETWEEN CEREBRAL CORTICAL ARCHITECTURE AND BLOOD CANCERS: THE DISEASE SPECTRUM IS DIFFERENT BECAUSE THE BRAINS LOOK DIFFERENT

EHA Library, Yue Wang, 4161944

CIRCULATING PLASMA LONG NON-CODING RNA GAS5 AS NON-INVASIVE BIOMARKER IN MULTIPLE MYELOMA PATIENTS

EHA Library, Anica Pravdić Divac, 4161945

HIGH EXPRESSION OF CIRCULATING MICRORNA-98 AND MICRORNA-4458 CORRELATES WITH POOR PROGNOSIS IN MULTIPLE MYELOMA PATIENTS.

EHA Library, Aneta Szudy-Szczyrek, 4161946

THE DIAGNOSTIC POTENTIAL OF CIRCULATING MICRORNA AND PLASMA GALECTIN-3 IN DISEASE PROGRESSION AND SKELETAL COMPLICATIONS IN MULTIPLE MYELOMA (MM)

EHA Library, Mosavar Farahani, 4161948

A WITHANOLIDE ANALOGUE INDUCES CELL CYCLE ARREST IN MULTIPLE MYELOMA CELL MODELS THROUGH KEY CANCER REGULATORS: IKAROS AND AIOLOS

EHA Library, Albane Zingg, 4161949

HARNESSING CNTN5: A NOVEL BIOMARKER FOR PRECISION RISK STRATIFICATION AND IMMUNE DYSFUNCTION MONITORING IN MULTIPLE MYELOMA

EHA Library, Vanessa Desantis, 4161950

ENHANCED MONITORING AND PROGNOSTIC INSIGHTS IN MULTIPLE MYELOMA USING HEVYLITE® ASSAY: A REAL-LIFE COMPREHENSIVE STUDY

EHA Library, Antonio Garcia-Guiñon, 4161951

EFFICACY AND SAFETY OF SELINEXOR-MELPHALAN COMBINED CONDITIONING REGIMEN FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA

EHA Library, Shuai Su, 4161952

REFRACTORY CYTOMEGALOVIRUS INFECTION AND PROLONGED IMMUNE DEFICIENCY FOLLOWING BCMA-DIRECTED CAR-T CELL THERAPY: IMPLICATIONS FOR INFECTIOUS DISEASE SURVEILLANCE AND MANAGEMENT

EHA Library, Yoko Tamamushi, 4161953

IMMUNOPHENOTYPIC DIFFERENCES AND IMMUNOMODULATORY MOLECULE EXPRESSION ON PLASMA CELLS IN MULTIPLE MYELOMA PATIENTS WITH VARYING DEGREES OF BONE MARROW INVOLVEMENT

EHA Library, Alicja Dudzik, 4161954

AMPLIFYING T CELL SPECIFIC ANTI-TUMOR IMMUNE RESPONSES VIA INDUCING IMMUNOGENIC CELL DEATH IN MULTIPLE MYELOMA IMMUNOTHERAPY

EHA Library, Zhaoyun Liu, 4161955

MECHANISMS OF THE KIDNEY-REINFORCING AND BLOOD CIRCULATION-ACTIVATING AND DREDGING COLLATERALS DECOCTION MEDICATED SERUM IN REGULATING MITOCHONDRIAL FISSION TO INDUCE AUTOPHAGY AND APOPTOSIS IN MULTIPLE MYELOMA U266 CELLS

EHA Library, Siyuan Cui, 4161956

CD56 EXPRESSION AS A PROGNOSTIC MARKER IN MULTIPLE MYELOMA: A RETROSPECTIVE COHORT STUDY

EHA Library, Gevorg Avagyan, 4161957

DARATUMUMAB: A MONOCLONAL ANTIBODY CAPABLE OF CAUSING DIAGNOSTIC ERRORS DUE TO KAPPA LIGHT CHAIN RESTRICTION IN DIFFERENT BONE MARROW CELLS.

EHA Library, JONE ALBERDI BALLINA, 4161958

SYSTEMATIC REVIEW OF BISPECIFIC ANTIBODIES EFFICACY AND SAFETY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Judith Pérez-Granado, 4161959

CHALLENGES IN MONOCLONAL PROTEIN DETECTION AND QUANTIFICATION: A TERTIARY HOSPITAL EXPERIENCE IN SOUTH KOREA

EHA Library, Mikyoung Park, 4161960

MINIMAL RESIDUAL DISEASE ASSESSMENT IN NEWLY DIAGNOSED MULTIPLE MYELOMA: A SINGLE-CENTER STUDY

EHA Library, Soudamini Mahapatra, 4161961

GASTROINTESTINAL SYMPTOMS AS AN INITIAL MANIFESTATION OF MULTIPLE MYELOMA: A CASE REPORT.

EHA Library, Nadia Bennai, 4161962

MONOCLONAL GAMMOPATHY IN THE α-2 REGION ON PROTEIN ELECTROPHORESIS: A CASE REPORT AND LITERATURE REVIEW

EHA Library, Mikyoung Park, 4161963

CLINICOPATHOLOGIC FEATURES OF 86 PATIENTS WITH TP53 MUTATED MULTIPLE MYELOMA

EHA Library, Fatima Zahra Jelloul, 4161964

BELANTAMAB MAFODOTIN PLUS BORTEZOMIB/DEXAMETHASONE SHOWS SIMILAR PROGRESSION-FREE SURVIVAL TO CILTACABTAGENE AUTOLEUCEL IN PATIENTS WITH RELAPSED /REFRACTORY MULTIPLE MYELOMA: A NETWORK META-ANALYSIS

EHA Library, Jun Ho Yi, 4161965

COMBINATION PARTNERS IMPACT ON OUTCOME OF CD38 ANTIBODY TREATMENT IN SECOND LINE: REAL WORLD DATA OF THE MULTIPLE MYELOMA REGISTRY OF THE EAST GERMAN STUDY GROUP HEMATOLOGY/ONCOLOGY (OSHO)

EHA Library, Sebastian Böttcher, 4161966

SOLUBLE BCMA AS A PROGNOSTIC BIOMARKER IN MULTIPLE MYELOMA: INSIGHTS FROM A META-ANALYSIS

EHA Library, Jaroslaw Dybko, 4161967

CD269 (BCMA) ANTIGEN EXPRESSION IN PATIENTS WITH SYSTEMIC AL-A.

EHA Library, Nelly Kashchavtseva, 4161968

BELANTAMAB MAFODOTIN + POMALIDOMIDE + DEXAMETHASONE (BPD) VS DARATUMUMAB + BORTEZOMIB + DEXAMETHASONE (DVD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: AN INDIRECT COMPARISON USING PATIENT-LEVEL DATA

EHA Library, Meral Beksac, 4161969

ANALYSIS OF THE PRELIMINARY RESULTS OF A PILOT REAL-WORLD STUDY OF APONERMIN COMBINED WITH KT-DECP REGIMEN IN RELAPSED/REFRACTORY MULTIPLE MYELOMA WITH PLASMACYTOMA

EHA Library, Aijun Liu, 4161970

CLINICAL ASSAY FOR PRECISION DIAGNOSIS, MONITORING AND INFORMING THERAPY OF MULTIPLE MYELOMA USING BONE MARROW OR PERIPHERAL BLOOD

EHA Library, Francois Aguet, 4161971

COMPARISON OF DIFFERENT CYCLOPHOSPHAMIDE DOSES FOR HEMATOPOIETIC STEM CELL MOBILIZATION IN MULTIPLE MYELOMA: A RETROSPECTIVE STUDY

EHA Library, Mehmet Sinan Dal, 4161972

QUANTITATIVE RISK OF UNDERLYING DISEASE CONDITIONS FOR PROGRESSION FROM MONOCLONAL GAMMOPATHY TO MULTIPLE MYELOMA: A NATIONWIDE COHORT STUDY

EHA Library, suein choi, 4161973

REAL-WORLD DURATION OF TREATMENT IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM) RECEIVING THE PROTEASOME INHIBITOR IXAZOMIB THROUGH THE GLOBAL IXAZOMIB EXPANDED ACCESS PROGRAM (EAP)

EHA Library, Efstathios Kastritis, 4161974

IXAZOMIB-BASED MAINTENANCE THERAPY IN REAL-WORLD PRACTICE FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

EHA Library, Liye Zhong, 4161975

EMERGING CARE MODELS OF TECLISTAMAB STEP-UP DOSING ADMINISTRATION IN REAL WORLD CLINICAL PRACTICE

EHA Library, Benjamin Derman, 4161976

TEMPORAL TRENDS IN ECOG PERFORMANCE SCORES IN MULTIPLE MYELOMA PATIENTS: A SIX-YEAR (2019-2024) RETROSPECTIVE ANALYSIS WITHIN THE EU4+UK MARKETS

EHA Library, Alessandra Franceschetti, 4161977

REAL-WORLD CHARACTERISTICS, TREATMENT, AND OUTCOMES IN MULTIPLE MYELOMA PATIENTS ON SECOND-LINE THERAPY: A MULTICENTER STUDY USING NATURAL LANGUAGE PROCESSING AND MACHINE LEARNING

EHA Library, Joaquín Martínez-López, 4161978

RAD21 SERVES AS A PROGNOSTIC INDICATOR IN MULTIPLE MYELOMA AND IS ASSOCIATED WITH HIGH-RISK GENETIC BACKGROUNDS

EHA Library, Yanling Wu, 4161980

OPTIMIZING BELANTAMAB MAFODOTIN IN TRIPLE-CLASS REFRACTORY MULTIPLE MYELOMA: IMPACT OF DOSE MODIFICATIONS ON KERATOPATHY INCIDENCE IN A REAL-WORLD RETROSPECTIVE STUDY

EHA Library, Lina Rüsing, 4161981

RIVAROXABAN FOR THE PREVENTION OF THROMBOEMBOLISM IN IMID-CONTAINING MYELOMA TREATMENT REGIMENS

EHA Library, Jamie Maddox, 4161982

PROSPECTIVE, SYSTEMATIC CLASSIFICATION OF CAUSES OF DEATH IN THE COURSE OF MULTIPLE MYELOMA

EHA Library, Jia xiang Jin, 4161983

SELECTION OF TREATMENT PLANS FOR PATIENTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA WITH RENAL IMPAIRMENT IN NOVEL AGENTS ERA: A SYSTEMATIC REVIEW AND META-ANALYSIS

EHA Library, Shaoxue Ding, 4161984

REAL-WORLD TREATMENT (TX) PATTERNS AND OUTCOMES IN PATIENTS (PTS) WITH MULTIPLE MYELOMA (MM): INSIGHTS FROM ARGENTINA AND BRAZIL (2018-2024)

EHA Library, Vania Hungria, 4161985

SECONDARY CLONES IDENTIFIED BY MASS SPECTROMETRY IN BASELINE SAMPLES REMAIN STABLE OR DISAPPEAR EARLY DURING MONITORING IN MULTIPLE MYELOMA PATIENTS

EHA Library, Oscar Berlanga, 4161986

IMPACT OF CUMULATIVE DOSE OF LENALIDOMIDE IN HEMATOLOGICAL PATIENTS ON THE DEVELOPMENT OF SECONDARY NEOPLASMS.

EHA Library, Gerardo Aguilar Monserrate, 4161987

FEATURES OF THE MOLECULAR LANDSCAPE OF MULTIPLE MYELOMA

EHA Library, Daria Chebykina, 4161988

CAN MITOCHONDRIAL DNA COPY NUMBER AND LEUKOCYTE TELOMERE LENGTH BE EFFECTIVE IN THE PROGNOSIS OF MULTIPLE MYELOMA?

EHA Library, Hasim Erol, 4161989

FROM MGUS TO MALIGNANCY: PROGNOSTIC FACTORS AND CLINICAL IMPLICATIONS

EHA Library, Aleksandra Sretenovic, 4161990

COMPARATIVE SAFETY OUTCOMES OF BCMA-DIRECTED VS. NON-BCMA BISPECIFIC ANTIBODIES IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): A SYSTEMATIC REVIEW AND META-ANALYSIS

EHA Library, Abat Khan, 4161991

AN INDIRECT COMPARISON OF ELRANATAMAB'S PATIENT-REPORTED OUTCOMES FROM MAGNETISMM-3 VERSUS REAL-WORLD EXTERNAL CONTROL ARMS IN TRIPLE-CLASS REFRACTORY MULTIPLE MYELOMA

EHA Library, Benjamin Hebraud, 4161992

CHRONIC HEPATITIS E INFECTIONS IN MULTIPLE MYELOMA: A HIDDEN THREAT IN THE ERA OF CAR-T AND BISPECIFIC ANTIBODIES

EHA Library, Ricardo Kosch, 4161993

DIAGNOSTIC VALUE OF 2D-STI ECHOCARDIOGRAPHIC MODEL IN MULTIPLE MYELOMA COMPLICATED WITH CARDIAC AMYLOIDOSIS

EHA Library, Chengcheng Fu, 4161994

THE SIGNIFICANCE OF A MGUS TUMOR BOARD: UPDATES AFTER THREE YEARS OF SUCCESS

EHA Library, Sandy Mazzoni, 4161995

EFFICACY AND SAFETY OF TALQUETAMAB AMONG HEAVILY PRE-TREATED PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA IN THE EXPANDED ACCESS PROGRAM AND COMMERCIAL SETTING

EHA Library, Sandy Mazzoni, 4161996

EPIDEMIOLOGY AND DISEASE ASSOCIATIONS OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE IN TAIWAN: A RETROSPECTIVE STUDY

EHA Library, Chao-Hung Wei, 4161997

CONCORDANCE BETWEEN BLINDED INDEPENDENT CENTRAL REVIEW COMMITTEE AND PHYSICIAN-ASSESSED RESPONSES, BASED ON A REAL-WORLD EXTERNAL CONTROL ARM IN RELAPSED/REFRACTORY MULTIPLE MYELOMA USING IMWG DATA

EHA Library, Brian G. Durie, 4161998

INCIDENCE OF HOSPITAL-ACQUIRED INFECTIONS AND ANALYSIS OF RISK FACTORS IN NEWLY ADMITTED PATIENTS WITH MULTIPLE MYELOMA

EHA Library, gongqiang wu, 4161999

MAGNETISMM-32: A PHASE 3 RANDOMIZED STUDY OF ELRANATAMAB VS EPD, PVD, OR KD IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) AND PRIOR ANTI-CD38-DIRECTED THERAPY

EHA Library, Thomas Chalopin, 4162000

YEAR-OVER-YEAR ONLINE MULTIPLE MYELOMA CURRICULUM IMPROVES THE COMPREHENSIVE MANAGEMENT SKILLS OF HEMATOLOGIST/ONCOLOGISTS

EHA Library, Sarah Elizabeth Bomba, 4162002

FAMILIAL MULTIPLE MYELOMA: CASE REPORT AND WHOLE EXOME SEQUENCING ANALYSIS

EHA Library, Yuanyuan Shao, 4162003

REAL-WORLD EFFICACY AND SAFETY OF POMALIDOMIDE-BASED TRIPLET THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MULTICENTER RETROSPECTIVE COHORT ANALYSIS

EHA Library, Li Bao, 4162005

ASSOCIATION OF DARATUMUMAB-BASED TREATMENT DURATION WITH REAL-WORLD SURVIVAL OUTCOMES IN CHINESE PATIENTS WITH MULTIPLE MYELOMA: EXPLORATORY ANALYSIS OF THE MMY4032 STUDY

EHA Library, Jin Lu, 4162006

COUNTRY VARIATIONS IN TREATMENT GOALS, EXPECTATIONS, AND EXPERIENCES AMONG PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Albert Oriol, 4162007

THE PROGNOSTIC VALUE OF RED BLOOD CELL DISTRIBUTION WIDTH IN AL AMYLOIDOSIS

EHA Library, Despina Fotiou, 4162008

BELANTAMAB MAFODOTIN, BORTEZOMIB, AND DEXAMETHASONE VS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: ANALYSIS OF THE CHINA SUBPOPULATION IN THE DREAMM-7 STUDY

EHA Library, Chengcheng Fu, 4162009

TREATMENT PATTERNS AT FIRST RELAPSE AND THEIR OUTCOMES IN MULTIPLE MYELOMA; A FINNISH RWD STUDY

EHA Library, Juha Lievonen, 4162010

REAL-WORLD TREATMENT PATTERNS AND CLINICAL OUTCOMES AMONG TRIPLE-CLASS-EXPOSED (TCE) PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) AND EXTRAMEDULLARY DISEASE (EMD)

EHA Library, Hans Lee, 4162011

REAL-WORLD TREATMENT PATTERNS AND OUTCOMES OF TRIPLE CLASS EXPOSED (TCE) PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED IN COMMUNITY AND ACADEMIC ONCOLOGY PRACTICES IN THE US

EHA Library, Saulius Girnius, 4162012

PAIN AND MULTIPLE MYELOMA: A THERAPEUTIC SYNERGY FOR IMPROVED QUALITY OF LIFE

EHA Library, Faten kallel, 4162013

DYNAMIC CHANGES OF PERIPHERAL BLOOD MONOCYTIC MYELOID-DERIVED SUPPRESSOR CELLS (MMDSCS) IN MULTIPLE MYELOMA

EHA Library, Li Bao, 4162014

LET'S GET TO THE HEART OF THE MATTER: EXAMINING THE PREVALENCE AND PREDICTORS OF CARDIOVASCULAR DISEASE IN MULTIPLE MYELOMA IN A LARGE REAL-WORLD DATASET

EHA Library, Romi Carriere, 4162015

MAINTENANCE THERAPY FOLLOWED AUTOLOGOUS STEM CELL TRANSPLANTATION BY IXAZOMIB,LENALIDOMIDE,OR IXAZOMIB IN COMBINATION WITH LENALIDOMIDE IN PATIENTS WITH MULTIPLE MYELOMA: A MULTI-CENTERED STUDY IN CHINA

EHA Library, Minqiu Lu, 4162017

REAL-WORLD DATA ON BRIDGING STRATEGIES, TOXICITY AND OUTCOMES OF RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED WITH CAR-T-CELLS

EHA Library, Jule Artzenroth, 4162018

VALIDATION AND REAL-WORLD APPLICATION OF THE NOVEL HIGH-RISK MULTIPLE MYELOMA CRITERIA BY THE IMS/IMWG CONSENSUS

EHA Library, Charalampos Filippatos, 4162019

EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN IN RR MULTIPLE MYELOMA, EXPERIENCE OF TUSCAN MYELOMA NETWORK

EHA Library, Sara Ciofini, 4162021

AUTO-BCMA-CART CELLS AS THE FIRST LINE MAINTENANCE THERAPY FOR MULTIPLE MYELOMA

EHA Library, Rong Fu, 4162022

EVALUATION OF DISEASE CHARACTERISTICS, TREATMENT STRATEGIES, AND OUTCOMES OF PATIENTS WITH EXTRAMEDULLARY MULTIPLE MYELOMA

EHA Library, Francesca Cottini, 4162023

LONG-TERM FOLLOW-UP FROM THE CHINA COHORT OF THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB (TEC) TREATMENT IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Juan Du, 4162024

THE CLINICAL SIGNIFICANCE OF IMMUNOGLOBULIN CLONAL ISOTYPE SWITCHING IN PATIENTS WITH MULTIPLE MYELOMA AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION

EHA Library, Lijing Shen, 4162025

THE IRD REGIMEN CONTINUED AFTER EFFECTIVE INDUCTION WITH DRD FOR TRANSPLANT-INELIGIBLE PATIENTS WITH MULTIPLE MYELOMA: A MULTI-CENTER PROSPECTIVE STUDY IN CHINA

EHA Library, Li Bao, 4162026

REAL-WORLD CLINICAL OUTCOMES OF DARATUMUMAB-BASED REGIMENS IN CHINESE PATIENTS WITH MULTIPLE MYELOMA BY RISK FACTOR: AN EXPLORATORY SUBGROUP ANALYSIS OF THE MMY4032 STUDY

EHA Library, Jin Lu, 4162027

IMPROVING DIAGNOSIS AND TREATMENT OF AL AMYLOIDOSIS IN THE CURRENT ERA: A SINGLE CENTRE RETROSPECTIVE ANALYSIS

EHA Library, NITIN GUPTA, 4162028

DIAGNOSTIC VALUE OF BORDERLINE SERUM FREE LIGHT CHAIN RATIO - SINGLE CENTER ANALYSIS

EHA Library, Jakub Radocha, 4162029

EXPLORING TUMOR-EDUCATED PLATELETS (TEPS) AS A NOVEL BIOMARKER SOURCE FOR MULTIPLE MYELOMA

EHA Library, Ana Bela Sarmento-Ribeiro, 4162031

ANALYSIS OF PROGNOSTIC FACTORS AFFECTING THE EFFICACY OF BCMA-TARGETED CAR-T THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Yi Wang, 4162032

AMBULATORY THROMBOPROPHYLAXIS AND INCIDENCE OF THROMBOSIS IN PATIENTS WITH MULTIPLE MYELOMA: A SECONDARY CARE CENTRE EXPERIENCE

EHA Library, Benjamin Lau, 4162033

VERIFICATION AND OPTIMIZATION OF VTE RISK STRATIFICATION SYSTEM FOR MULTIPLE MYELOMA IN CHINA BASED ON REVIEW COHORT

EHA Library, yuexiao liu, 4162034

REAL-WORLD COMPARISON OF TREATMENT OUTCOMES FOR MYELOMA IN ELDERLY TRANSPLANT INELIGIBLE PATIENTS RECEIVING FIRST-LINE VRD, RD AND VCD: RESULTS FROM THE ANZ MYELOMA AND RELATED DISEASES REGISTRY

EHA Library, Sarah Zhao, 4162035

WORSE SURVIVAL OUTCOME IN NEW ZEALAND PATIENTS WITH MULTIPLE MYELOMA COMPARING AUSTRALIA - A RETROSPECTIVE COHORT STUDY FROM THE MYELOMA AND RELATED DISEASES REGISTRY (MRDR)

EHA Library, Jian Li, 4162036

EARLY TREATMENT DISCONTINUATION (ETD) OR DEATH (ED) IN MULTIPLE MIELOMA PATIENTS TREATED FRONT-LINE WITH BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE (VRD)

EHA Library, Gladys Ibarra, 4162038

GLUD1 IS HIGHLY EXPRESSED IN NEWLY DIAGNOSED MULTIPLE MYELOMA AND PROMOTES DISEASE PROGRESSION

EHA Library, Qiuwen Mi, 4162039

THE VALUE OF PERIPHERAL BLOOD LYMPHOCYTE SUBSETS IN PREDICTING THE PROGNOSIS OF NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Rong Fu, 4162040